News >

Simon Shares Insight on Emerging Immunotherapy Regimens in NSCLC

Danielle Bucco
Published: Wednesday, Feb 21, 2018

George R. Simon, MD

George R. Simon, MD
Following the success of single-agent immunotherapy, multiple studies are investigating immunotherapy combination strategies for patients with non–small cell lung cancer (NSCLC), according to George R. Simon, MD.

State of the Science Summit™ on Advanced Non–Small Cell Lung Cancer, Simon, a professor in the Department of Thoracic/Head and Neck Medical Oncology in the Division of Cancer Medicine at The University of Texas MD Anderson Cancer Center, discussed emerging advancements with immunotherapy combination strategies for patients with NSCLC.

OncLive: Please provide an overview of your presentation on frontline combination strategies in NSCLC.

Simon: I discussed immunotherapy combinations in the first-line setting for the treatment of patients with NSCLC. These consist of combining immunotherapy with chemotherapy or combining immunotherapy with another immunotherapy agent.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: New Directions in Advanced Cutaneous Squamous Cell Carcinoma: Emerging Evidence of ImmunotherapyAug 13, 20191.5
Advances in™ Therapies for Patients With ALK-Positive Lung Cancers: More Options…More Decisions…Better OutcomesAug 30, 20191.5
Publication Bottom Border
Border Publication
x